StockNews.AI
GMED
StockNews.AI
62 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc.  - GMED

1. Pomerantz LLP is investigating claims against Globus Medical for potential securities fraud. 2. Globus reported Q1 2025 earnings missing estimates and experiencing revenue decline. 3. Stock price fell 22.96% following the disappointing earnings report. 4. CEO cited soft deal closures and supply chain disruptions as impacts on performance. 5. Investors are encouraged to join the class action investigation.

4m saved
Insight
Article

FAQ

Why Bearish?

Globus's significant earnings miss and subsequent stock decline may indicate ongoing investor concerns. Historical precedents show that similar situations often lead to further depreciation in stock value due to declining investor confidence.

How important is it?

Investors may react strongly to ongoing investigations and recent performance data, leading to potential price impacts. The rise in litigation surrounding GMED indicates concerns that may sway both current and potential investors.

Why Short Term?

The immediate investigation and stock decline suggest potential volatility, but may stabilize once legal uncertainties are resolved. However, if more fraudulent actions are confirmed, the impact could extend.

Related Companies

SPINEZBHSYK
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Globus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 8, 2025, Globus issued a press release reporting its financial results for the first quarter of 2025.  Among other items, Globus reported non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06, and revenue of $598.12 million, missing consensus estimates by $27.78 million and representing a 1.4% year-over-year decline.  Globus’s President and Chief Executive Officer said that the Company’s “first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders[.]”  On this news, Globus’s stock price fell $16.64 per share, or 22.96%, to close at $55.82 per share on May 9, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.  CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News